ArticleBMC health services research2026
Reforming China's retail prescription medicine purchasing system: evidence from retail pharmacies in Wuhan.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tiered diagnosis and value-based healthcare: can the outpatient reimbursement policy for medical costs in retail pharmacies promote both?BMC health services research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn China, national health reforms are interpreted, piloted and implemented slightly differently by each local health authority. This is the first study of China's 2023 pharmacy reform allowing 360 million urban employee basic medical insurance (UEBMI) members the right to purchase prescription medicine using their insurance at retail pharmacies. For Wuhan, we assess the impact of the 2023 medicine purchasing reform on medicine buying behavior; evaluate the benefits of the changes to UEBMI members; and provide new insights into China's retail pharmacies' business model.
methodsFrom March 2022 to December 2023, we gained unique access to daily UEBMI members' medicine purchases, covering 34,956 claims at two representative Wuhan pharmacies. The impact of the new retail pharmacy purchasing policy on medicines purchasing behavior were quantitatively evaluated using descriptive statistics and interrupted time series analysis (ITSA).
resultsNo significant pre-reform trend in medicine purchases was observed, confirming a stable baseline prior to the 2023 reform. However, medicine purchases from retail pharmacies showed a significant upward trend. There was no evidence of medicine over-use or fraud. The benefit to members was measured by the absence of any significant upward per capita total expenditure trend and a significant decrease in the proportion of medicine expenditures from members personal medical savings accounts. Retired UEBMI members benefited more than currently employed UEBMI members from allowing UEBMI funds for prescription purchases from retail pharmacies.
conclusionsThe 2023 reforms allowed UEBMI members to purchase medicine from retail pharmacies, providing medicine accessibility and affordability for members, especially retired members; did not trigger an increase in members' medicine consumption; attenuated the over-use of hospital pharmacies. Future study should empirically test whether pharmacies' business model transformed away from a singular focus on price competition towards a combination of price competition and health services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.